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Abstract
Children and adolescents with overweight and obesity are a global health concern. This is an integrative overview of six
Cochrane systematic reviews, providing an up-to-date synthesis of the evidence examining interventions for the treatment of
children and adolescents with overweight or obesity. The data extraction and quality assessments for each review were
conducted by one author and checked by a second. The six high quality reviews provide evidence on the effectiveness of
behaviour changing interventions conducted in children <6 years (7 trials), 6–11 years (70 trials), adolescents 12–17 years
(44 trials) and interventions that target only parents of children aged 5–11 years (20 trials); in addition to interventions
examining surgery (1 trial) and drugs (21 trials). Most of the evidence was derived from high-income countries and
published in the last two decades. Collectively, the evidence suggests that multi-component behaviour changing
interventions may be beneﬁcial in achieving small reductions in body weight status in children of all ages, with low adverse
event occurrence were reported. More research is required to understand which speciﬁc intervention components are most
effective and in whom, and how best to maintain intervention effects. Evidence from surgical and drug interventions was too
limited to make inferences about use and safety, and adverse events were a serious consideration.
Introduction
Excess weight in children and adolescents is a growing
public health crisis [1–3], with inequalities occurring in
populations from different socioeconomic [4–6] and ethnic
groups [7–10].
Children and adolescents with obesity can develop a
number of serious related comorbidities. These include
musculoskeletal conditions [11], cardiovascular risk factors
such as hypertension, insulin resistance, and hyperlipidae-
mia [12], respiratory conditions, including sleep apnoea
[13] or asthma [14], and digestive diseases such as non-
alcoholic fatty liver disease [15]. Psychosocial well-being
can also be affected, with young people with obesity more
susceptible to stigmatisation [16], reduced self-esteem and
quality of life [17]. Evidence also demonstrates that obesity
in childhood tracks into adulthood [18, 19], thus increasing
the risk of ill health later in life [20, 21].
Given the complex nature of obesity, there is unlikely to
ever be one treatment regime that will be effective across all
populations, with the most suitable intervention approach
determined by the child’s age and degree of excess weight,
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amongst other considerations. Treatment options range
from lifestyle modiﬁcation interventions, to the use of
bariatric surgery and drugs.
The least invasive and most widely used approach to
treating obesity in childhood is lifestyle modiﬁcation. These
programmes aim to improve dietary quality, increase phy-
sical activity levels and reduce sedentary behaviours, often
incorporating behaviour changing techniques to help sustain
positive changes and prevent relapse. Many interventions
have a family focus, with parents deﬁned as the “agents for
change”, particularly in children under 12 years [22].
Forms of bariatric surgery include gastric bypass, sleeve
gastrectomy and gastric banding [23]. Drugs used to treat
obesity include: Sibutramine an appetite suppressant that,
while still licensed in Brazil, was suspended by the Eur-
opean Medicine Agency and withdrawn by the Food and
Drug Administration (FDA) in 2010 due to adverse cardi-
ovascular effects; Orlistat, a fat absorption inhibitor that has
been approved by the FDA but only for children ≥ 12 years
old [24]. Other drugs frequently used off license to treat
obesity in childhood include: metformin, an anti-diabetic
medication [25, 26] and ﬂuoxetine, an antidepressant [27].
New drugs targeting appetite regulation are currently under
development or evaluation.
The aim of this review was to conduct an integrative
overview of six Cochrane reviews [28–33], to provide a
comprehensive update to the previous Cochrane review on
interventions for treating obesity in children [34].
This overview was written to help inform ongoing work
by the World Health Organization on the management of
children and adolescents with overweight and obesity.
Methods
We conducted this overview of reviews in accordance with
the recommendations for Cochrane overviews of reviews
[35]. PROSPERO (CRD42016053423). All reviews pro-
duced to update the Oude Luttikhuis (2009) review [34]
were included.
A detailed description of the methods can be found in the
online supplementary appendix 1. In brief, data was
extracted using a standardised data collection form, and
review quality was assessed using the revised Assessment
of Multiple Systematic Reviews (R-AMSTAR) measure-
ment tool [36], by one reviewer and checked for accuracy
by a second reviewer, with disagreements resolved by
consensus. Each R-AMSTAR assessment was conducted by
reviewers who were not authors of the original review.
The primary outcomes of interest were changes in BMI
or BMI z-score, with results from relevant meta-analyses
extracted alongside secondary outcomes as reported in the
summary of ﬁndings tables. The original review authors’
Cochrane ‘risk of bias’ assessment [37] and Grading of
Recommendations Assessment, Development and Evalua-
tion (GRADE) assessment were also extracted.
Results
Characteristics of included studies
The characteristics of the six included reviews and the
Randomised Controlled Trials (RCTs) included in each
review are shown in the appendix: Supplementary
Tables S1 and S2 (online Supplementary ﬁle), respectively.
All six reviews were published between 2015 and 2017, and
included RCTs with a minimum of six months data from
baseline. Across all reviews a total of 163 studies (19,756
participants) were included, representing trials conducted
between 1968 and 2016, from 30 countries. The vast
majority of studies were undertaken in the USA (n= 73,
45%) or Europe (n= 44, 27%), with only 16 (10%) studies
conducted in upper-middle-income countries, while the
remainder were conducted in high-income countries.
(According to the World Bank list of economies (July 2016)
http://siteresources.worldbank.org/DATASTATISTICS/
Resources/CLASS.XLS) Most studies were published
within the last two decades.
The number of trials included in each review varied
substantially from just one trial included in the surgery
review [28], to 70 trials included in the review of lifestyle
interventions in children aged 6–11 years [32]. Most trials
were individually randomised, with a small number of
cluster trials (n= 11) across all six reviews. The median
sample sizes for included studies within each review ranged
from 50 to 96, with individual trial samples sizes within
reviews ranging from just 10–686 participants. Participant
views (e.g., satisfaction with, or opinions of the interven-
tion) were not reported in any of the surgery or drug trials,
and were only reported in 23 trials across the four lifestyle
reviews.
Participants
Every review excluded children who were critically ill or
diagnosed with a syndromic form of obesity. Where
applicable, pregnant and breast feeding females were also
excluded. All reviews included children with obesity, and
the four lifestyle intervention reviews also examined chil-
dren with overweight (median BMI z-score across the life-
style reviews was between 2.2 and 2.3, although calculated
using a variety of different growth references). The surgery
and drug reviews included any child under the age of
18 years. A priori mean age groups were set for trials
included in the lifestyle reviews to ensure each trial was
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only included in one review (the lifestyle interventions
targeting the child and parent, or child alone were reviewed
in the following age groups: up to 6, 6–11 and 12–17 years;
for lifestyle interventions targeting the parent as the sole
agent for change, an age range of 5–11 years was included).
The median proportion of females in each review ranged
from 54 to 65%, and reporting of socioeconomic status and
ethnicity was limited.
Interventions
All reviews in this series examined the effectiveness of
interventions that aimed to treat children or adolescents with
overweight or obesity. One review [28] examined the
effectiveness of bariatric surgery, another [29] studied drug
interventions, whilst the remaining reviews [30–33] exam-
ined the effectiveness of lifestyle interventions that deliv-
ered diet, physical activity and behavioural interventions
either as a single or multicomponent programme. Of these,
Loveman (2015) [30] focused on parent-only interventions
whilst Colquitt (2016) [31], Mead (2017) [32] and Al-
Khudairy (2017) [33] examined any lifestyle intervention
by age group of the participating child. Interventions could
be undertaken in any setting, although more than half of the
trials (n= 85) were undertaken in either primary or sec-
ondary care.
Comparators
Comparators in each of the six reviews included true control
(placebo or no intervention) (n= 38), usual care (deﬁned by
either the study author or reviewer) (n= 72) or an alter-
native concomitant therapy providing it was delivered in
both the intervention and comparator arms (n= 53).
Outcome measures
All six reviews examined the same primary outcome mea-
sures (BMI / BMI z-score, body weight and adverse events)
and secondary outcome measures (health-related quality of
life; self-esteem; all-cause mortality; morbidity; body fat
distribution; behaviour change; participants’ views of the
intervention; socioeconomic effects).
Methodological quality of included reviews
The R-AMSTAR assessment results for each review are
shown in supplementary appendix Table S3. All six reviews
scored between 35 and 41, out of a possible 44, and were
therefore deemed of good methodological quality. Areas
where all reviews were marked down included not provid-
ing a clinical consensus statement and not adequately
describing statistical tests.
Risk of bias of included randomised controlled trials
The bias associated with the included trials varied across the
six reviews (Appendix Table S4, supplementary ﬁle). In
general random sequence generation was rated as low risk
of bias for the majority of included studies. Allocation
concealment was generally rated low or unclear risk of bias.
Performance bias (i.e. not blinding study participants and
personnel) was rated as high or unclear risk for the majority
of the non-drug trials. Detection bias (i.e. not blinding
outcome assessment) varied across the reviews, with lower
risk of bias for objective outcomes (which included body
mass measurements). Attrition bias (Attrition bias was
determined by assessing the completeness of the outcome
data, including attrition and exclusions from the analysis.)
(i.e., incomplete data), was rated as unclear or high risk, in
over half of all trials included in each review. Selective
reporting bias (i.e., differences between reported and unre-
ported ﬁndings) was generally poor in a large proportion of
trials in each review. The proportion of trials with low risk
of other biases varied across the reviews.
Quality of evidence from randomised controlled
trials in the included reviews
Each of the six reviews assessed overall quality of the
evidence using the GRADE method which is shown in the
summary of ﬁndings (Supplementary appendix:
Tables S5A–E,). Overall, the quality of the evidence was
low for BMI and, where provided, was very low or low for
other outcomes measured in the reviews. No studies pro-
vided data on socioeconomic effects. Reasons for down-
grading BMI evidence included: high risk of bias (e.g.,
attrition), imprecision (wide conﬁdence intervals), and
inconsistency (heterogeneity).
Effects of interventions
Summary of ﬁndings (Supplementary appendix:
Tables S5A–E), and BMI and BMI z-score outcome ana-
lyses (Supplementary appendix: Table S6) are presenting in
the supplementary ﬁle.
Lifestyle interventions for the treatment of overweight or
obesity
The vast majority of evidence (141 out of 163 trials)
reviewed in this overview were lifestyle interventions (i.e.
those that addressed diet, physical activity and / or beha-
viour change). This evidence was assessed across four
reviews, examining the effectiveness of interventions
delivered to the child, or parent and child across infancy,
pre adolescence and adolescence. This was supplemented
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by a further review that speciﬁcally examined interventions
that targeted parents as the sole agent for change in their
child. The results are summarised below.
Interventions for pre-school children up to the age of 6
years
Colquitt et al. (2016) [31] conducted searches up to March
2015 and identiﬁed seven completed and four ongoing
trials. Of the seven completed trials (923 participants), six
tested multicomponent interventions and one tested a diet-
ary intervention. Trials were undertaken in four countries
(one upper-middle income) in a variety of settings, and all
were published from 2009. The mean age of participants
ranged from 2 to 5 years, and the median of the mean
baseline BMI z-score was 2.25. The proportion of female
and white participants ranged from 25 to 80% and 47 to
91%, respectively. The duration and nature of the inter-
vention and comparators varied across the studies, and
whilst all seven trials reported a period of post intervention
follow-up ranging in duration from 6 to 32 months, follow-
up data were only available for ﬁve studies.
When the multicomponent interventions were compared
with control (usual care, enhanced usual care, or informa-
tion provision) at the end of the intervention (6 to
12 months), a reduction in BMI z-score was observed in
favour of the intervention: mean difference (MD)
−0.3 units (95% CI: −0.4 to −0.2) (210 participants; four
trials). This reduction was maintained at both 12 to
18 months follow-up from baseline (6–8 months post
intervention) (MD −0.4 units (95% CI: −0.6 to −0.2); 202
participants; four trials), and at 2 years follow-up from
baseline (12 months post intervention) (MD −0.3 units
(95% CI: −0.4 to −0.1); 96 participants; one trial). Three
out of the four multicomponent studies also assessed par-
ental weight change (parents were required to have a BMI
of least 25 or 27 kg/m2 to be included). Results from the
parental weight change analysis revealed an overall mean
difference of −4.69 kg (95% CI: −7.27 to −2.11) in favour
of the intervention, measured at the end of the intervention
(three trials, 146 participants, low quality evidence). This
reduction appeared to be sustained at 12–24 months follow-
up (6–12 months post intervention).
Only one very low quality trial examined the effective-
ness of an energy restricted (57 participants) and dairy rich
(59 participants) diets, and reported a small reduction in
BMI z-score (MD −0.1 units [95% CI: −0.11 to −0.09]),
but this reduction was maintained at 36 months in only the
dairy rich arm. Only one trial documented adverse events
stating that none had occurred. Three trials reported health-
related quality of life, with improvement shown in some,
but not all domains, whilst behaviour change and parent–
child relationships were reported inconsistently. No data
were reported for all-cause mortality, morbidity, and socio-
economic effects.
A large cluster RCT (n= 475) was included in the
review but not included in the meta-analysis due to possible
methodological bias. This trial demonstrated a statistically
non-signiﬁcant change in BMI z-score (MD: −0.05 units
[95% CI: −0.14 to 0.04]) over the one year intervention (no
post intervention follow-up data was provided).
Interventions for school aged children under 12 years
Lifestyle interventions targeting parents as the sole agents
for change Loveman et al. (2015) [30] conducted searches
up to March 2015, and identiﬁed 20 trials and ten ongoing
studies. The 20 trials comprised of 3057 participants, and
reported a median mean baseline age of 8 years, a median
female proportion of ~60%, and where reported a median
baseline BMI z-score of 2.2 in the intervention group and
2.3 in the control group. The proportion of white partici-
pants ranged from 54 to 100%. All but one trial were
published from 2000 onwards, and were conducted in seven
countries (one upper-middle income). The sample size of
individual trials ranged from 15 to 645 and the duration of
the intervention ranged from 2.25 to 24 months. All but
three trials included a period of post intervention follow-up
ranging from 2.75 to 18.5 months, giving rise to a follow-up
from baseline ranging from 5.5 to 24 months. Whilst the
content of the interventions varied considerably, the com-
parators also differed, and so the outcomes were meta-
analysed by comparator group.
BMI z-score was the most frequently reported outcome
measure. The mean difference in BMI z-score at longest
follow-up (10 to 24 months) was −0.04 units (95% CI:
−0.15 to 0.08) for three trials (267 participants) comparing
parent-only intervention with parent child intervention. A
similar statistically non-signiﬁcant change in BMI z-score
was seen when comparing parent-only interventions to
minimal contact control interventions at the longest follow-
up period (9 to 12 months), with a mean difference of
−0.01 units (95% CI: −0.07 to 0.09) (one trial,
165 participants). For the two trials (136 participants)
comparing parent-only interventions with a waiting list
control, a statistically signiﬁcant change in BMI z-score was
observed in favour of the intervention at the longest follow-
up period (10 to 12 months) with a mean difference of
−0.10 units (95% CI: −0.19 to −0.01). Where the
comparator was a concomitant intervention, no meta-
analysis was reported due to a very high degree of
heterogeneity (I2= 94%).
Secondary outcomes reported in the summary of ﬁndings
table included parent–child relationships which were
assessed in three studies (low quality evidence): two
demonstrated a small effect in favour of the parent-only
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intervention and one showed no effect. Whilst two studies
reported that no serious adverse events occurred, generally
adverse events were not reported. Data on morbidity, all-
cause mortality and socioeconomic effects were not
reported.
Lifestyle interventions targeting the child-only, or child and
parent Mead et al. (2017) [32], conducted searches up to
July 2016 and identiﬁed 70 trials (8,461 participants), four
of which were cluster trials, and 20 ongoing studies.
Although the vast majority of trials included both the child
and parent/care giver (n= 65) and comprised a dietary,
physical activity and behavioural component (n= 49), the
delivery and content of the interventions varied con-
siderably. Individual trial sample sizes ranged from 16 to
686 participants, with a median mean age of 10 years at
baseline (with only 15 trials including participants with a
mean age of <9 years). The median proportion of female
participants was approximately 55% (ranging from 26 to
100%). Where reported, the median proportion of white
participants was 80 and 71% in the intervention and control
arms, respectively (ranging from 0 to 100%). Median of the
mean BMI z-score at baseline was 2.2 (ranging from 1.3 to
5.6), the duration of the interventions ranged from
0.25–24 months, and follow-up from baseline ranged from
5.5–36 months. Just over half of the trials (n= 37) had a
period of post intervention follow-up, with a median dura-
tion of 10 months.
The majority of trials (n= 63) were published from 2000.
Trials took place in 18 high-income countries and three
upper-middle-income countries. Setting varied signiﬁcantly
across studies, although half (n= 36) took place in primary
or secondary care. Fifteen trials evaluated an additional
element as part of a concomitant intervention, and were
consequently analysed separately. A further two separate
analyses were also conducted for the four cluster trials and
two maintenance trials. Of these separately assessed trials,
two of the clusters were subject to methodological queries
which precluded them from analysis, and the remaining
studies did not demonstrate any substantial impact on BMI.
Twenty four trials reporting BMI could be pooled for
analysis, and demonstrated a change in BMI in favour of the
intervention (measured at last available point of follow-up) of
−0.53 kg/m2 (95% CI: −0.82 to −0.24); 2785 participants).
Thirty-seven trials reported BMI z-score suitable for meta-
analysis, which resulted in a change in favour of intervention
(measured at last available point of follow-up) of−0.06 units,
(95% CI: −0.10 to −0.02); 4019 participants).
As the main meta-analyses revealed signiﬁcant hetero-
geneity, subgroup analyses were conducted to examine the
impact of: type of intervention, type of comparator, risk of
attrition bias, setting of intervention, duration of post
intervention follow-up period, parental involvement and
severe obesity at baseline. None of the subgroup analyses
gave rise to a consistent effect that differed signiﬁcantly
from the overall pooled effect for both BMI and BMI z-
score. However, subgroup analysis of BMI by duration of
post intervention follow-up period (no post intervention
follow-up [15 trials] vs. follow-+up at: <6 [3 trials], 6–12
[2 trials] and >12 [4 trials] months) demonstrated that
intervention effects only remained signiﬁcant immediately
post intervention. A similar pattern was also observed for
BMI z-score, although it did not reach signiﬁcance. These
ﬁndings align with data from the two trials
(263 participants) identiﬁed in this review that speciﬁcally
examined the impact of a post intervention maintenance
period on BMI z-score and found no signiﬁcant intervention
effect.
Thirty-one trials documented whether serious adverse
events occurred, although the vast majority (n= 29)
reported zero occurrence. In the two trials that reported a
serious adverse event occurrence, examples included
inﬂuenza, muscular-skeletal surgery or injuries, however
none were considered to be related to the study. Six trials
reported a range of adverse events in a small percentage of
participants (examples included elevated triglycerides,
blood pressure and cholesterol in both groups in one trial,
and a range of accidents, infections, and skin rashes across
groups, none of which were deemed to be related to the
trial). Only a small number of trials reported secondary
outcomes with data suitable for meta-analysis: parent
reported and child reported health-related quality of life
was reported in ﬁve trials (718 participants) and three trials
(164 participants), respectively; two trials reported on self-
esteem (144 participants); two trials (168 participants)
reported change in caloric intake; and six trials
(744 participants) reported accelerometry measured physi-
cal activity. However, none of the analyses demonstrated a
signiﬁcant difference between intervention and control.
Two trials (55 participants) reported minutes per day of TV
viewing, and found a small signiﬁcant reduction of 6.6 min
per day in favour of the intervention. The data on morbidity,
all-cause mortality and socioeconomic effects were not
reported.
Interventions for children 12 years and older
Al-Khudairy et al. (2017) [33] conducted searches up to
July 2016, and 44 trials (4781 participants; median mean
age at baseline: 14.3 years), and 50 ongoing studies were
identiﬁed. All studies (apart from two) were published
between 2000 and 2017, and were conducted in 15 coun-
tries (with ﬁve trials conducted in four upper-middle-
income countries). The duration of the interventions ranged
from 6 weeks to 2 years, with follow-up from baseline
ranging from 24 weeks to 2 years, with a post intervention
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follow-up period (median length 6 months; range 1–
21 months) in just over half of all studies. The setting and
content of the interventions varied considerably across the
trials; ﬁve trials focused solely on physical activity inter-
ventions, ﬁve on diet only interventions, and 34 on multi-
component interventions. Sample size ranged from 10 to
521 participants. Median of the mean (and range) baseline
BMI and BMI z-score across the studies in the intervention
groups were 32.4 kg/m2 (26.6–45.5 kg/m2) and 2.2 units
(1.92–4.2 units), respectively, and in the control groups
31.84 kg/m2 (26.6–45.5 kg/m2) and 2.2 units (1.81–4.3
units), respectively. The median proportion of female par-
ticipants was 55.8% in the intervention groups and 54.5% in
the controls (ranging from 0–100%); in the 19 trials
reporting ethnicity, the proportion and range of white par-
ticipants was 58.8% for the intervention groups and 34.8%
for the controls (ranging from 0–100%).
For the trials that could be pooled for meta-analysis, the
overall mean difference in change in BMI at the last available
measurement point was −1.18 kg/m2 (95% CI: −1.67 to
−0.69) (2774 participants; 28 trials), while the change in BMI
z-score was −0.13 units (95% CI: −0.21 to −0.05) (2399
participants; 20 trials). This reduction remained when examined
in those trials with long (18–24 months) follow-up from
baseline: BMI −1.49 kg/m2 (95 CI: −2.56 to −0.41) (760
participants; six trials) and BMI z-score −0.34 units (95% CI:
−0.66 to −0.02) (602 participants; ﬁve trials). As expected
intervention effects were larger when compared to no inter-
vention or usual care, than those compared to concomitant
interventions. The length of the post intervention follow-up
period had no signiﬁcant effects on BMI. Further subgroup
analyses revealed that the type of intervention (multi-
component, physical activity only or diet only) had little effect
on outcomes although the vast majority of trials were multi-
component. Similarly, parental involvement in the intervention,
the intervention setting, mode, and theoretical basis of inter-
vention did not signiﬁcantly alter the overall effect estimates.
Only ﬁve trials documented adverse events, three of which
reported no events; one stated 6.4% of participants experienced
an adverse event (but no further details provided) and only one
reported the occurrence of adverse events documented as ran-
ging from 19 to 25%. Seven trials (972 participants) demon-
strated an improvement in health-related quality of life at a
follow-up of 6 to 24 months (SMD 0.44 (95% CI: 0.09 to
0.79)). Lifestyle related behaviours were measured too incon-
sistently to summarise, while measures of all-cause mortality,
morbidity and socioeconomic effects were not reported.
Drug interventions for the treatment of obesity in children
and adolescents
Mead et al. (2016) [29] conducted searches up to March
2016 and identiﬁed 21 trials (11 metformin [including one
trial arm with Metformin and Fluoxetine], six Sibutramine,
four Orlistat), and eight ongoing studies. Duration of the
interventions ranged from 2.75 to 12.5 months, with dura-
tion of follow-up (from baseline) ranging from 5.5 to
23 months. It is important to note that only four trials
reported post intervention follow-up. In total 2484 children
(mean baseline age range 10–16 years [median 13.7 years],
mean baseline BMI range 26–42 kg/m2 [median ~35 kg/m2])
participated in the included trials, which were undertaken in
secondary care settings and conducted in the last two dec-
ades (1999–2010). The trials took place in 12 different
countries (four upper-middle income) with an individual
trial sample size ranging from 24 to 539 participants,
and completion rates ranging from 36 to 100% (median
78.6%).
Eighteen trials were placebo controlled, and 17 of these
also included a concomitant lifestyle intervention. Ethnicity
was clearly reported in 10 out of the 21 trials with the
proportion of white participants ranging from 37 to 92%.
BMI was meta-analysed for 16 trials (1884 participants) at
6 months (14 trials) and 12 months (two trials), which was
the end of the active intervention in all but one trial. A small
but statistically signiﬁcant mean difference in BMI was
observed: −1.3 kg/m2 (95% CI: −1.9 to −0.8) in favour of
the intervention. When these data were analysed by drug
type, Sibutramine, Metformin and Orlistat all demonstrated
a reduction in BMI. Additional subgroup analyses indicated
statistically signiﬁcant differences, favouring studies with
higher dropout and from middle-income countries. The
most common adverse events were: gastrointestinal in the
Orlistat and Metformin trials; and tachycardia, constipation
and hypertension in the Sibutramine trials. Serious adverse
events were reported in ﬁve trials (1347 participants)
resulting in a relative risk of 1.43 (95% CI: 0.63 to 3.25).
Health-related quality of life was only reported in two trials
(86 participants), with no signiﬁcant between group differ-
ences seen in the trial reporting ﬁndings from the SF36
health questionnaire. One suicide was reported in an Orlistat
group. Morbidity was reported in only one trial (533 par-
ticipants) resulting in a small between group difference in
new gallstone development in an Orlistat arm. Data on
socioeconomic effects were not reported.
Surgery for the treatment of obesity in children and
adolescents
Ells et al. (2015) [28] conducted searches up to March 2015,
and identiﬁed one recent Australian RCT examining the
effectiveness of a laparoscopic adjustable band compared to
a multicomponent lifestyle intervention (usual care). Fifty
predominantly female adolescent participants with severe
obesity (mean age 16 years, mean BMI over 40), took part
in the trial. Between baseline and last point of measurement
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(24 months) participants in the surgery arm experienced a
signiﬁcant 12.7 kg/m2 (95% CI: 11.3 to 14.2) reduction in
BMI compared to a reduction of 1.3 kg/m2 (95% CI: 0.4 to
2.9) in the control arm. The surgery participants also
experienced improvements in two of eight quality of life
concepts, when compared to the control. Post intervention
morbidity (metabolic syndrome) was reported in four
patients completing the control arm and no patients in the
intervention arm. No other secondary outcome data were
reported. Four ongoing studies were identiﬁed which may
help strengthen future evidence for surgery interventions in
this population group.
Discussion
This overview provides a comprehensive update to Oude
Luttikhuis, 2009 [34]. However, despite a dramatic increase
in the number of trials conducted over the last eight years,
overall the ﬁndings remain similar. The outcomes also align
with more recent systematic reviews of parent-only inter-
ventions;[38, 39] educational interventions to treat obesity
in 6- to 12-year-old children;[40] school-based interven-
tions [41] and lifestyle interventions for children up to 18
years [42]. BMI z-score change by age group also followed
a similar pattern to changes reported in a recent observa-
tional study [43].
All six reviews provided good quality evidence with high
R-AMSTAR scores, thus providing a high degree of con-
ﬁdence in the review ﬁndings and clinical relevance [36].
However, the overall quality of the trials included in the
reviews was low, with improvement required across most of
the risk of bias domains, but in particular attrition and
selective reporting. Performance bias was also an identiﬁed
risk in many of the non-drug trials, reﬂecting the difﬁculties
in blinding lifestyle and surgical interventions.
Implications for research
Despite a sizeable evidence base, there remain a number of
important gaps (Table 1). Therefore, serious consideration
should be given to ensuring all new trials follow the
CONSORT criteria, use standardised outcome assessment
criteria and validated measurement tools, to facilitate com-
parisons across trials. Trials co-ordinators should also
ensure that long-term (>12 month) post intervention follow
ups are conducted, and details on all adverse events and
maintenance periods are clearly and consistently reported.
Authors should use the TIDieR checklist [44] to provide
comprehensive and reproducible trial descriptions (clearly
describing both the control and intervention conditions,
given the differences that can arise in usual care provision),
and must ensure: (1) trials are adequately powered; (2)
attrition is accounted for in an appropriate intention to treat
analysis (i.e. the use of multiple imputation); (3) interven-
tion cost is included; and (4) where possible study personnel
are blinded.
Conducting more qualitative research to understand the
barriers and facilitators to weight management in different
populations would be advantageous, as would more process
evaluations [45]. These studies may help guide imple-
mentation, tailor interventions to populations needs, and
understand which approaches may work better for which
populations and why.
Implications for practice
It is important to note that the vast majority of the evidence
was generated in high-income countries, thus calling into
question the generalisability of these ﬁndings in low- and
middle-income countries. This is particularly important
given the most rapid recent rises in overweight in young
children from low- and lower-middle-income countries [1],
and lack of cost-effectiveness data, making it difﬁcult to
effectively translate ﬁndings for lower income countries
with potentially different health and political economies.
Only one trial of bariatric surgery was identiﬁed that
provides insufﬁcient evidence to assess the wider
Table 1 Outstanding research questions
What weight management interventions are most effective in low
and middle-income countries?
What weight management interventions are most effective for
children with disabilities, complex health needs or very severe forms
of obesity?
What weight management interventions are most effective in speciﬁc
ethnic, religious and culturally diverse groups?
How cost effective are child and adolescent weight management
programmes?
What are the key intervention components that promote success?
What are the key family characteristics/environments that promote
success?
What is the optimal role of parents within different age groups?
What behaviour change strategies are most useful?
What maintenance programmes are required to help improve the
sustainability of positive weight management improvements?
What are the beneﬁts of dual family weight management i.e.
interventions that address weight management in overweight
children and overweight parents simultaneously in the same
intervention?
What are the impacts of emerging new technologies such as e-health
in children?
What are the long-term beneﬁts, and safety of drug interventions in
children and adolescents with obesity?
How clinically effective is restrictive or mal-absorptive bariatric
surgery in treating obesity in adolescents from different
backgrounds?
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applicability and acceptability of this approach. A recent
non-RCT study including 242 adolescents undergoing bar-
iatric surgery at ﬁve U.S. centres reported signiﬁcant
improvements in weight, cardio-metabolic health, and
weight-related quality of life 3 years post-surgery. How-
ever, associated risks included speciﬁc micronutrient deﬁ-
ciencies and the need for additional abdominal procedures
[46]. A recent French review concluded that bariatric sur-
gery is not a simple surgical intervention in teenagers, with
minor side effects reported in 10–15%, and severe side
effects in 1–5% [47].
Drug interventions were also assessed, however, some of
the trial drugs were used off license, or have been with-
drawn in some countries, which coupled to the lack of long-
term follow-up and safety data, makes it impossible to make
any conclusive recommendations.
From the lifestyle modiﬁcation reviews, the largest (0.3
unit) BMI z-score reduction was observed in the interven-
tions targeting the youngest children (2–5 years), although
this was by far the smallest evidence base. However, given
the tracking of excess weight into later childhood [48, 49] it
is important to observe the effectiveness of early interven-
tion to help prevent excess weight persisting into later
childhood. Early treatment may also be important given the
smallest overall reduction in BMI z-score (0.06 units) was
observed in interventions delivered to children aged 6–11
years. This ﬁnding may reﬂect the challenges of intervening
in this age group, who may be more inﬂuenced by the wider
obesogenic environment than their younger counterparts.
This age group may also be less autonomous than their
older adolescent peers and may therefore rely more on
parental support, yet the exact role of parents and parental
weight status is not clearly described. This ﬁnding warrants
further consideration given the association between parental
and child obesity [50].
While any reduction in BMI z-score for children with
overweight and obesity may be of clinical beneﬁt, the BMI
z-score reduction required to ameliorate any comorbidities
is less clear. For example, a small observational study in
young people (median age 12.4 years) with severe obesity
reported that a reduction of 0.25 BMI z-score units was
required to improve adiposity and metabolic health [51].
However, improvements in cholesterol were observed in
children with obesity aged 7–17 years with a BMI z-score
reduction of <0.1 unit [52], and improvement in insulin and
cholesterol was observed in 5–19 year olds with obesity,
following a BMI z-score reduction of 0.15 (SD 0.5) units
[53]. Reduction of systemic blood pressure and arterial
stiffness was also reported in pre-pubertal children with
obesity following a BMI z-score reduction of 0.1 unit [54].
The differences in BMI z-score associated cardio-metabolic
changes may also be affected by the use of different refer-
ence populations used to calculate the BMI z-score
(Farpour–Lambert personal communication). In addition to
any clinical beneﬁt, it is important to consider the public
health beneﬁts of even small BMI/BMI z-score reductions if
feasibly achieved across an entire population [55].
As BMI it is not a direct measure of body composition,
changes in fat mass may be confounded with changes in fat-
free mass. This is particularly important, given the data
from the UK [56], US [57] and Australia [58] demonstrates
increases in central adiposity exceeding increases in BMI in
children. Although other body composition measures were
not the focus of this overview given variations in the use,
cost and precision, each review did show (as a secondary
outcome) other body composition indices were reported in
the individual trials. Waist circumference was the most
frequently reported measure, however, meta-analyses of this
outcome were only reported in the reviews of children [32]
6–11 years (ﬁnal follow-up: MD −2.41 cm, 95% CI −3.59
to −1.23; P < 0.0001; 11 trials; 1325 participants) and 12–
17 years [33] (ﬁnal follow-up: MD −2.26 cm, 95% CI
−3.80 to −0.72; P= 0.004; 17 trials; 1997 participants),
thus demonstrating a parallel reduction in waist cir-
cumference and BMI as a result of lifestyle interventions in
school age children.
Although intervention content, format and delivery var-
ied signiﬁcantly both within and across the included
reviews, collectively there was evidence to support the role
of multicomponent interventions. There was also no clear
difference in terms of outcome according to setting, which
may suggest that intervention content and wider context
may be more important than delivery setting. Very little
data were provided on the role of the family characteristics
or the wider environment. Although the inclusion of parents
in both the school age (6–11 years) and adolescent (12–17
years) studies did not appear to signiﬁcantly impact on the
overall effect of the intervention, speciﬁcally targeting
children and parents with overweight in the preschool (up to
6 years) review seemed to demonstrate a dual beneﬁt to
both children and their parents. Workniak et al. [59]. also
showed that parental weight status change was an inde-
pendent predictor of child weight status change in a family-
based weight management study of children 8–12 years.
Parents have an important role in controlling their child’s
food and activity environment, helping their child attend
treatment sessions and implement changes. Thus, intensity
of parental involvement [60] and their role as an inﬂuential
role models [61], may all be important contributors to
effective long-term paediatric weight management.
The sustainability of any observed reduction in BMI/
BMI z-score is a key consideration. Whilst effects appeared
to be sustained in the adolescent and preschool aged chil-
dren, data from children aged 6–11 suggests effects were
not sustainable. Given obesity is a chronic relapsing disease
[62] manifested in an obesity conducive environment, it is
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perhaps unsurprising that short-term effects do not persist
particularly in children who may be most inﬂuenced by
their wider environment.
Data on adverse events were generally not well reported
across the studies in any of the lifestyle reviews, but where
reported occurrence was low. However adverse events such
as effects on linear growth, injuries, eating disorders and
psycho-social well-being must be considered. Bariatric
surgery is a major surgical intervention, with serious
potential risks for operative and perioperative complications
and mortality. The restrictive or mal-absorptive nature of
some forms of bariatric surgery presents an additional
consideration in growing children. Psychological maturity,
ability to provide informed consent, the availability of
family support, and provision of ongoing post-operative
lifestyle support [63] should be considered. Drug
interventions are also not without adverse events, which
depending on the drug prescribed, include a variety of
gastrointestinal and cardiovascular conditions.
In summary, this overview provides a comprehensive
update on the effectiveness of obesity treatments for children
2–18 years. However, it is essential that when translated into
practice, ﬁndings are interpreted within the context of local
political and health systems, and population needs (Table 2).
It is also important to acknowledge the limitations of RCT
evidence when evaluating complex interventions. It may
therefore be important to consider additional observational
studies, where gaps remain in the RCT evidence.
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Table 2 Practical considerations when implementing ﬁndings in
practice
Evidence from surgical and drug RCTs was too limited to make
inferences about use and safety, and adverse events were a serious
consideration.
Lifestyle interventions can be successful in producing small
reductions in BMI z-score with relatively low occurrence of adverse
events. However obesity is a chronic relapsing condition, therefore it
may be challenging to sustain changes over the longer term, thus
ongoing maintenance support will be required.
As there is currently insufﬁcient evidence to suggest which particular
setting or intervention component may be more or less beneﬁcial, it
may be useful to consider the following:
○ Take a multi-component approach incorporating nutrition,
physical activity and behaviour change components.
○ Identify high risk groups and ensure services are accessible and
appropriate for them: can reasonable adjustments be made to
improve inclusivity?
○ Co-production: develop interventions with target populations, to
tailor the intervention to local needs (e.g. language/cultural
adaptations; co-morbidity management; tailored time, location
and delivery style). This may also help reduce attrition and poor
compliance which can be problematic.
○ Effective communication: how best do you reach your target
population and referring staff (e.g. available networks, social
media, TV, radio, print)?
○ A truly family-based approach – ensuring support is in place for
all family members with weight concerns.
○ The inﬂuence of the wider environment (food taxes, availability
of healthy food and drink; and opportunities to be active), and
local systems (personal resources and staff training; ﬁnancial
coverage of treatment)
○ Ensure comprehensive systems are in place to record adverse
events.
○ The needs of complex families (i.e. families in crisis, child
protection issues, severe parental or child psychiatric illness)
who are unlikely to participate in trials.
○ Consider the scalability of any intervention, and the cost to both
to the provider and participants.
○ Evaluate and learn from local implementation, by using
standardised and validated outcome measurement tools.
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